Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02339129 · ClinicalTrials.gov registry record · Phase 2
Dosing Interval Study of SST-0225 Topical Ibuprofen Cream in the Treatment of Delayed Onset Muscle Soreness
A Phase 2 study, sponsored by Strategic Science & Technologies.
- Completed
- Registry status
- Phase 2
- Development phase
- 72
- Enrollment target
NCT02339129 is a Phase 2 study that has completed, run by Strategic Science & Technologies. The registered enrollment target is 72 participants.
The verdict
NCT02339129, a Phase 2 study, has completed, sponsored by Strategic Science & Technologies.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 72 participants
- Enrollment target
Study Summary
This is a Phase 2, prospective, randomized, dual-center, double-blind, placebo-controlled, parallel-group study designed to determine the dosing interval, efficacy and safety of SST-0225 (5.4 grams, applied up to 6 times in 24 hours, over a 48-hour dosing period) for the treatment of pain associated with DOMS.
Interventions
- DRUG Placebo
- DRUG SST-0225
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 72 participants |
| Start Date | 2014-11 |
| Est. Completion | 2015-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02339129
The ClinicalTrials.gov registry entry for NCT02339129 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 72 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Strategic Science & Technologies, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02339129 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02339129 about?
NCT02339129 is a clinical study titled "Dosing Interval Study of SST-0225 Topical Ibuprofen Cream in the Treatment of Delayed Onset Muscle Soreness". This is a Phase 2, prospective, randomized, dual-center, double-blind, placebo-controlled, parallel-group study designed to determine the dosing interval, efficacy and safety of SST-0225 (5.4 grams, applied up to 6 times in 24 hours, over a 48-hour dosing period) for the treatment of pain associated...
What is the current status of trial NCT02339129?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 72 participants. The study started on 2014-11. Estimated completion is 2015-03.
What interventions are being tested in trial NCT02339129?
The interventions under investigation include: Placebo (DRUG), SST-0225 (DRUG).
Who is sponsoring clinical trial NCT02339129?
This trial is sponsored by Strategic Science & Technologies, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.